Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agilon Health (AGL) Cash & Current Investments: 2020-2024

Historic Cash & Current Investments for Agilon Health (AGL) over the last 5 years, with FY2024 value amounting to $400.0 million.

  • Agilon Health's Cash & Current Investments fell 2088.76% to $310.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $310.9 million, marking a year-over-year decrease of 2088.76%. This contributed to the annual value of $400.0 million for FY2024, which is 1809.69% down from last year.
  • As of FY2024, Agilon Health's Cash & Current Investments stood at $400.0 million, which was down 1809.69% from $488.3 million recorded in FY2023.
  • Agilon Health's Cash & Current Investments' 5-year high stood at $1.0 billion during FY2021, with a 5-year trough of $106.8 million in FY2020.
  • Over the past 5 years, Agilon Health's median Cash & Current Investments value was $488.3 million (recorded in 2023), while the average stood at $582.5 million.
  • In the last 5 years, Agilon Health's Cash & Current Investments soared by 87386.49% in 2021 and then crashed by 4432.95% in 2023.
  • Annual analysis of 5 years shows Agilon Health's Cash & Current Investments stood at $106.8 million in 2020, then surged by 873.86% to $1.0 billion in 2021, then fell by 15.66% to $877.2 million in 2022, then plummeted by 44.33% to $488.3 million in 2023, then dropped by 18.1% to $400.0 million in 2024.
  • Its Cash & Current Investments stands at $400.0 million for FY2024, versus $488.3 million for FY2023 and $877.2 million for FY2022.